Latest Conference Articles

Dapagliflozin Effective in T2D with HFrEF Regardless of Type of Background T2D Therapy

Dapagliflozin Effective in T2D with HFrEF Regardless of Type of Background T2D Therapy

June 19th 2020

ADA

VIDEO: Kieran Docherty, MBChB, discusses results of the DAPA-HF analysis on the impact of background T2D therapy on clinical outcomes in patients with T2D and HFrEF.

Glycemic Control in US Youth, Young Adults Disappointing

Glycemic Control in US Youth, Young Adults Disappointing

June 17th 2020

ADA

ADA 2020. Average A1c for a recent young cohort with type 2 diabetes was 8.5%, according to research presented at the ADA Virtual Scientific Sessions.

Physician CKD Awareness in T2D Patients Linked to CKD Severity

Physician CKD Awareness in T2D Patients Linked to CKD Severity

June 17th 2020

ADA

Physicians’ CKD awareness in T2D is linked with CKD severity, suggests a new study presented this week at the American Diabetes Association’s 80th Virtual Scientific Sessions.

DAPA-HF: Dapagliflozin Reduces Incident T2D in Adults with Heart Failure

DAPA-HF: Dapagliflozin Reduces Incident T2D in Adults with Heart Failure

June 16th 2020

ADA

VIDEO: Silvio Inzucchi, MD, discusses results of a prespecified analysis of the DAPA-HF trial, which found that dapagliflozin reduced new onset diabetes by 32% in patients with heart failure.

Rushed HCP Interactions with Black Patients Erode Glycemic Control

Rushed HCP Interactions with Black Patients Erode Glycemic Control

June 16th 2020

ADA

ADA 2020: Glycemic control was worse for black patients who experienced hurried interaction with healthcare providers than for those who did not, a new study reports.

Intensive Telehealth Program Improves A1c In Rural Patients with Type 2 Diabetes

Intensive Telehealth Program Improves A1c In Rural Patients with Type 2 Diabetes

June 15th 2020

ADA

ADA 2020. Improvement in glycemic control among US veterans was seen across 5 study sites and was sustained at 18 months after study initiation, says study reported at the ADA 80th Virtual Scientific Sessions.

Novel Once-weekly Basal Insulin Found Comparable to QD Insulin Glargine

Novel Once-weekly Basal Insulin Found Comparable to QD Insulin Glargine

June 15th 2020

ADA

ADA 2020. An investigational once-weekly insulin proved comparable in safety and efficacy to traditional once-daily insulin glargine in findings presented at the ADA 80th Annual Virtual Scientific Sessions.

Dapagliflozin Reduces Incident T2D in Patients with HFrEF

Dapagliflozin Reduces Incident T2D in Patients with HFrEF

June 15th 2020

ADA

ADA 2020. Dapagliflozin reduced new onset type 2 diabetes in patients with heart failure with reduced ejection fraction, according to a study released today at the ADA 80th Virtual Scientific Sessions.

ADA2020: SGLT-2 Inhibitor Delays Insulin Initiation, Intensification in T2D with CVD

ADA2020: SGLT-2 Inhibitor Delays Insulin Initiation, Intensification in T2D with CVD

June 14th 2020

ADA

ADA2020: Empagliflozin significantly, durably delays need for insulin and for large dose increases, in patients with type 2 diabetes and cardiovascular disease, finds study presented at ADA 80th Scientific Sessions.

ADA: Next Generation “Artificial Pancreas” Improves Glycemic Control, A1c in T1D

ADA: Next Generation “Artificial Pancreas” Improves Glycemic Control, A1c in T1D

June 13th 2020

ADA

ADA 2020: A new automatic insulin delivery system improves glycemic control in young people with type 1 diabetes, according to research presented at the American Diabetes Association Virtual Scientific Sessions.